The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California
The Oncology Institute (NASDAQ: TOI) has received certification to administer Pluvicto therapy in their outpatient California radiation oncology practices. This radiopharmaceutical treatment for metastatic prostate cancer has traditionally been administered in hospital settings. TOI will become one of the few community-based practices on the West Coast offering radiopharmaceuticals in an outpatient setting, aiming to reduce hospitalization costs and provide value for patients and payors.
L'Istituto di Oncologia (NASDAQ: TOI) ha ricevuto la certificazione per somministrare terapia con Pluvicto nelle loro pratiche di radioterapia oncologica ambulatoriale in California. Questo trattamento radioterapico per il cancro prostatitico metastatico è stato tradizionalmente somministrato in contesti ospedalieri. TOI diventerà una delle poche pratiche comunitarie sulla Costa Ovest a offrire farmaci radioterapici in un contesto ambulatoriale, con l'obiettivo di ridurre i costi di ospedalizzazione e offrire valore ai pazienti e ai pagatori.
El Instituto de Oncología (NASDAQ: TOI) ha recibido la certificación para administrar terapia con Pluvicto en sus prácticas de oncología radioterapéutica ambulatoria en California. Este tratamiento radiofármaco para el cáncer de próstata metastásico se ha administrado tradicionalmente en entornos hospitalarios. TOI se convertirá en una de las pocas prácticas comunitarias en la Costa Oeste que ofrece radiofármacos en un entorno ambulatorio, con el objetivo de reducir los costos de hospitalización y proporcionar valor a los pacientes y a los pagadores.
온콜로지 연구소(NASDAQ: TOI)가 캘리포니아의 외래 방사선 종양학 치료 관행에서 플루빅토 요법을 관리하기 위한 인증을 받았습니다. 전이성 전립선암에 대한 이 방사성 의약품 치료는 전통적으로 병원 환경에서 시행되었습니다. TOI는 외래 환경에서 방사성 의약품을 제공하는 서부 해안의 몇 안 되는 지역 사회 기반 진료 중 하나가 되어 입원 비용을 줄이고 환자와 지불자에게 가치를 제공하는 것을 목표로 하고 있습니다.
L'Institut d'Oncologie (NASDAQ: TOI) a reçu la certification pour administrer la thérapie Pluvicto dans ses pratiques d'oncologie radiothérapeutique ambulatoire en Californie. Ce traitement radiopharmaceutique pour le cancer de la prostate métastatique a traditionnellement été administré dans des environnements hospitaliers. TOI deviendra l'une des rares pratiques communautaires sur la côte Ouest à proposer des radiopharmaceutiques en ambulatoire, visant à réduire les coûts d'hospitalisation et à offrir de la valeur aux patients et aux payeurs.
Das Onkologie-Institut (NASDAQ: TOI) hat die Zertifizierung für die Durchführung von Pluvicto-Therapie in ihren ambulanten strahlenonkologischen Praxen in Kalifornien erhalten. Diese radiopharmazeutische Behandlung für metastasierenden Prostatakrebs wurde traditionell in Krankenhausumgebungen angewendet. TOI wird eine der wenigen gemeindebasierten Praxen an der Westküste sein, die Radiopharmazeutika im ambulanten Bereich anbietet, mit dem Ziel, die Krankenhauskosten zu senken und den Patienten und Kostenträgern einen Mehrwert zu bieten.
- Expansion into radiopharmaceutical treatment services
- Potential cost reduction through outpatient administration
- Competitive advantage as one of few West Coast community-based providers
- None.
Insights
This certification represents a notable strategic expansion for TOI in the competitive oncology market. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a targeted radioligand therapy that has shown significant efficacy in treating PSMA-positive metastatic castration-resistant prostate cancer. By offering this treatment in outpatient settings, TOI gains a competitive advantage in the West Coast market while potentially reducing treatment costs by
The move into radiopharmaceuticals could drive substantial revenue growth, as Pluvicto treatments typically cost
TOI will be one of the few community-based practices on the West Coast to offer radiopharmaceuticals in the outpatient setting.
CERRITOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) announced that they have received certification to begin administering Pluvicto therapy in their outpatient California radiation oncology practices. Pluvicto, a radiopharmaceutical used to treat certain types of metastatic prostate cancer, has previously been administered primarily in hospital settings.
“We are ecstatic about the opportunity to offer this new therapeutic alternative to our patients,” said Dr. Geoffrey Geiger, Medical Director of Radiation Oncology at TOI. “This aligns perfectly with TOI’s mission to deliver state-of-the-art therapy in the community and provide value for our patients and payor partners.”
Jeremy Castle, Chief Operations Officer, added, “The launch of our radiopharmaceutical program marks a significant step forward in our radiation oncology growth strategy. By providing this treatment in the outpatient setting, we can reduce the need for costly hospitalizations, benefiting patients, payors, and our organization alike. It’s a win for all involved”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
What new treatment certification did TOI receive in California for 2024?
How will TOI's Pluvicto therapy certification benefit patients?
Where will TOI offer Pluvicto therapy in 2024?
What makes TOI's Pluvicto therapy offering unique on the West Coast?
